Combining SGLT2 inhibition with a thiazolidinedione additively attenuate the very early phase of diabetic nephropathy progression in type 2 diabetes mellitus

Frontiers in Endocrinology

Volumn 9, Issue JUL, 2018, Pages

  Han, Eugene ^a,b   Shin, Eugene ^b   Kim, Gyuri ^b   Lee, Ji Yeon ^b   Lee, Yong ho ^b   Lee, Byung Wan ^b   Kang, Eun Seok ^b   Cha, Bong Soo ^b  

^a Keimyung University School of Medicine   (South Korea)

^b Yonsei University College of Medicine   (South Korea)

Author keywords

Db db mice; Diabetic nephropathy; Sodium glucose co transporter 2 inhibitor; Thiazolidinedione; Type 2 diabetes

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ANGIOTENSINOGEN; COLLAGEN TYPE 1; COLLAGEN TYPE 4; DAPAGLIFLOZIN; GLUCOSE; INTERLEUKIN 6; MONOCYTE CHEMOTACTIC PROTEIN 1; PALMITIC ACID; PIOGLITAZONE; SODIUM GLUCOSE COTRANSPORTER 2; TRANSFORMING GROWTH FACTOR BETA;

ALBUMINURIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL DEATH; CELL SURVIVAL; CELL VIABILITY ASSAY; COMBINATION DRUG THERAPY; CONTROLLED STUDY; DIABETIC NEPHROPATHY; DISEASE COURSE; DRUG EFFECT; DRUG EFFICACY; DRUG TARGETING; GENE EXPRESSION; GLOMERULUS; GLOMERULUS BASEMENT MEMBRANE; HISTOPATHOLOGY; HK-2 [HUMAN KIDNEY] CELL LINE; HUMAN; HUMAN CELL; INFLAMMATION; KIDNEY CORTEX; KIDNEY FUNCTION; KIDNEY HYPERTROPHY; KIDNEY PROXIMAL TUBULE; MALE; MORPHOLOGY; MOUSE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PODOCYTE; PODOCYTE FOOT PROCESS; PROTEIN EXPRESSION;

EID: 85050382549     PISSN: None     EISSN: 16642392     Source Type: Journal    
DOI: 10.3389/fendo.2018.00412     Document Type: Article

References (39)

1. Jung CH, Jang JE, Park JY. A novel therapeutic agent for type 2 diabetes mellitus: SGLT2 inhibitor. Diabet Metab J. (2014) 38:261-73. doi: 10.4093/dmj.2014.38.4.261
2. Bailey CJ, Gross JL, Pieters A, Bastien A, List JF. Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with metformin: a randomised, double-blind, placebo-controlled trial. Lancet (2010) 375:2223-33. doi: 10.1016/S0140-6736(10)60407-2
3. Ferrannini E, Ramos SJ, Salsali A, Tang W, List JF. Dapagliflozin monotherapy in type 2 diabetic patients with inadequate glycemic control by diet and exercise: a randomized, double-blind, placebo-controlled, phase 3 trial. Diabet Care (2010) 33:2217-24. doi: 10.2337/dc10-0612
4. Han S, Hagan DL, Taylor JR, Xin L, Meng W, Biller SA, et al. Dapagliflozin, a selective SGLT2 inhibitor, improves glucose homeostasis in normal and diabetic rats. Diabetes (2008) 57:1723-9. doi: 10.2337/db07-1472
5. Macdonald FR, Peel JE, Jones HB, Mayers RM, Westgate L, Whaley JM, et al. The novel sodium glucose transporter 2 inhibitor dapagliflozin sustains pancreatic function and preserves islet morphology in obese, diabetic rats. Diabet Obes Metab. (2010) 12:1004-12. doi: 10.1111/j.1463-1326.2010.01291.x
6. Jurczak MJ, Lee HY, Birkenfeld AL, Jornayvaz FR, Frederick DW, Pongratz RL, et al. SGLT2 deletion improves glucose homeostasis and preserves pancreatic beta-cell function. Diabetes (2011) 60:890-8. doi: 10.2337/db10-1328
7. Merovci A, Solis-Herrera C, Daniele G, Eldor R, Fiorentino TV, Tripathy D, et al. Dapagliflozin improves muscle insulin sensitivity but enhances endogenous glucose production. J Clin Invest. (2014) 124:509-14. doi: 10.1172/JCI70704
8. Tahara A, Kurosaki E, Yokono M, Yamajuku D, Kihara R, Hayashizaki Y, et al. Effects of SGLT2 selective inhibitor ipragliflozin on hyperglycemia, hyperlipidemia, hepatic steatosis, oxidative stress, inflammation, and obesity in type 2 diabetic mice. Eur J Pharmacol. (2013) 715:246-55. doi: 10.1016/j.ejphar.2013.05.014
9. Han E, Kim MS, Kim YS, Kang ES. Risk assessment and management of post-transplant diabetes mellitus. Metab Clin Exp. (2016) 65:1559-69. doi: 10.1016/j.metabol.2016.07.011
10. Corzo C, Griffin PR. Targeting the peroxisome proliferator-activated receptor-gamma to counter the inflammatory milieu in obesity. Diabet Metab J. (2013) 37:395-403. doi: 10.4093/dmj.2013.37.6.395
11. Liao HW, Saver JL, Wu YL, Chen TH, Lee M, Ovbiagele B. Pioglitazone and cardiovascular outcomes in patients with insulin resistance, pre-diabetes and type 2 diabetes: a systematic review and meta-analysis. BMJ Open. (2017) 7:e013927. doi: 10.1136/bmjopen-2016-013927
12. Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med. (2007) 356:2457-71. doi: 10.1056/NEJMoa072761
13. Vallon V, Rose M, Gerasimova M, Satriano J, Platt KA, Koepsell H, et al. Knockout of Na-glucose transporter SGLT2 attenuates hyperglycemia and glomerular hyperfiltration but not kidney growth or injury in diabetes mellitus. Am J Physiol Renal. (2013) 304:F156-67. doi: 10.1152/ajprenal.00409.2012
14. Andrikopoulos S, Blair AR, Deluca N, Fam BC, Proietto J. Evaluating the glucose tolerance test in mice. Am J Physiol Endocrinol Metab. (2008) 295:E1323-32. doi: 10.1152/ajpendo.90617.2008
15. Huang MY, Chaturvedi LS, Koul S, Koul HK. Oxalate stimulates IL-6 production in HK-2 cells, a line of human renal proximal tubular epithelial cells. Kidney Int. (2005) 68:497-503. doi: 10.1111/j.1523-1755.2005.00427.x
16. Wei W, An XR, Jin SJ, Li XX, Xu M. Inhibition of insulin resistance by PGE1 via autophagy-dependent FGF21 pathway in diabetic nephropathy. Sci Rep. (2018) 8:9. doi: 10.1038/s41598-017-18427-2
17. Xie X, Yi W, Zhang P, Wu N, Yan Q, Yang H, et al. Green tea polyphenols, mimicking the effects of dietary restriction, ameliorate high-fat diet-induced kidney injury via regulating autophagy flux. Nutrients (2017) 9:497. doi: 10.3390/nu9050497
18. Xin W, Zhao X, Liu L, Xu Y, Li Z, Chen L, et al. Acetyl-CoA carboxylase 2 suppression rescues human proximal tubular cells from palmitic acid induced lipotoxicity via autophagy. Biochem Biophys Res Commun. (2015) 463:364-9. doi: 10.1016/j.bbrc.2015.05.070
19. Lim JC, Lim SK, Han HJ, Park SH. Cannabinoid receptor 1 mediates palmitic acid-induced apoptosis via endoplasmic reticulum stress in human renal proximal tubular cells. J Cell Physiol. (2010) 225:654-63. doi: 10.1002/jcp.22255
20. Pistrosch F, Herbrig K, Kindel B, Passauer J, Fischer S, Gross P. Rosiglitazone improves glomerular hyperfiltration, renal endothelial dysfunction, and microalbuminuria of incipient diabetic nephropathy in patients. Diabetes (2005) 54:2206-11. doi: 10.2337/diabetes.54.7.2206
21. Makino H, Miyamoto Y, Sawai K, Mori K, Mukoyama M, Nakao K, et al. Altered gene expression related to glomerulogenesis and podocyte structure in early diabetic nephropathy of db/db mice and its restoration by pioglitazone. Diabetes (2006) 55:2747-56. doi: 10.2337/db05-1683
22. Marumo T, Yagi S, Kawarazaki W, Nishimoto M, Ayuzawa N, Watanabe A, et al. Diabetes induces aberrant DNA methylation in the proximal tubules of the kidney. J Am Soc Nephrol. (2015) 26:2388-97. doi: 10.1681/ASN.2014070665
23. Ko GJ, Kang YS, Han SY, Lee MH, Song HK, Han KH, et al. Pioglitazone attenuates diabetic nephropathy through an anti-inflammatory mechanism in type 2 diabetic rats. Nephrol Dial Transpl. (2008) 23:2750-60. doi: 10.1093/ndt/gfn157
24. Bao Y, Jia RH, Yuan J, Li J. Rosiglitazone ameliorates diabetic nephropathy by inhibiting reactive oxygen species and its downstream-signaling pathways. Pharmacology (2007) 80:57-64. doi: 10.1159/000103232
25. Wang XX, Levi J, Luo Y, Myakala K, Herman-Edelstein M, Qiu L, et al. SGLT2 protein expression is increased in human diabetic nephropathy: SGLT2 protein inhibition decreases renal lipid accumulation, inflammation, and the development of nephropathy in diabetic mice. J Biol Chem. (2017) 292:5335-48. doi: 10.1074/jbc. M117.779520
26. Tang L, Wu Y, Tian M, Sjostrom CD, Johansson U, Peng XR, et al. Dapagliflozin slows the progression of the renal and liver fibrosis associated with type 2 diabetes. Am J Physiol Endocrinol Metab. (2017) 313:E563-76. doi: 10.1152/ajpendo.00086.2017
27. Terami N, Ogawa D, Tachibana H, Hatanaka T, Wada J, Nakatsuka A, et al. Long-term treatment with the sodium glucose cotransporter 2 inhibitor, dapagliflozin, ameliorates glucose homeostasis and diabetic nephropathy in db/db mice. PLoS ONE (2014) 9:e100777. doi: 10.1371/journal.pone.0100777
28. Gallo LA, Ward MS, Fotheringham AK, Zhuang A, Borg DJ, Flemming NB, et al. Once daily administration of the SGLT2 inhibitor, empagliflozin, attenuates markers of renal fibrosis without improving albuminuria in diabetic db/db mice. Sci Rep. (2016) 6:26428. doi: 10.1038/srep26428
29. Kern M, Kloting N, Mark M, Mayoux E, Klein T, Bluher M. The SGLT2 inhibitor empagliflozin improves insulin sensitivity in db/db mice both as monotherapy and in combination with linagliptin. Metab Clin Exp. (2016) 65:114-23. doi: 10.1016/j.metabol.2015.10.010
30. Panchapakesan U, Pegg K, Gross S, Komala MG, Mudaliar H, Forbes J, et al. Effects of SGLT2 inhibition in human kidney proximal tubular cells-renoprotection in diabetic nephropathy? PLoS ONE (2013) 8:e54442. doi: 10.1371/journal.pone.0054442
31. Wanner C, Inzucchi SE, Lachin JM, Fitchett D, von Eynatten M, Mattheus M, et al. Empagliflozin and progression of kidney disease in type 2 diabetes. N Engl J Med. (2016) 375:323-34. doi: 10.1056/NEJMoa1515920
32. Nagata T, Fukuzawa T, Takeda M, Fukazawa M, Mori T, Nihei T, et al. Tofogliflozin, a novel sodium-glucose co-transporter 2 inhibitor, improves renal and pancreatic function in db/db mice. Br J Pharmacol. (2013) 170:519-31. doi: 10.1111/bph.12269
33. Chow F, Ozols E, Nikolic-Paterson DJ, Atkins RC, Tesch GH. Macrophages in mouse type 2 diabetic nephropathy: correlation with diabetic state and progressive renal injury. Kidney Int. (2004) 65:116-28. doi: 10.1111/j.1523-1755.2004.00367.x
34. Deji N, Kume S, Araki S, Soumura M, Sugimoto T, Isshiki K, et al. Structural and functional changes in the kidneys of high-fat diet-induced obese mice. Am J Physiol Renal Physiol. (2009) 296:F118-26. doi: 10.1152/ajprenal.00110.2008
35. De Nicola L, Gabbai FB, Liberti ME, Sagliocca A, Conte G, Minutolo R. Sodium/glucose cotransporter 2 inhibitors and prevention of diabetic nephropathy: targeting the renal tubule in diabetes. Am J Kidney Dis. (2014) 64:16-24. doi: 10.1053/j.ajkd.2014.02.010
36. Wolf G, Ziyadeh FN. Molecular mechanisms of diabetic renal hypertrophy. Kidney Int. (1999) 56:393-405. doi: 10.1046/j.1523-1755.1999.00590.x
37. Feliers D, Kasinath BS. Mechanism of VEGF expression by high glucose in proximal tubule epithelial cells. Mol Cell Endocrinol. (2010) 314: 136-42. doi: 10.1016/j.mce.2009.09.009
38. Ruster C, Wolf G. Angiotensin II as a morphogenic cytokine stimulating renal fibrogenesis. J Am Soc Nephrol. (2011) 22:1189-99. doi: 10.1681/ASN.2010040384
39. Re RN. Mechanisms of disease: local renin-angiotensin-aldosterone systems and the pathogenesis and treatment of cardiovascular disease. Nat Clin Pract Cardiovasc Med. (2004) 1:42-7. 10.1038/ncpcardio0012